Pfizer Inc. (NYSE:PFE) Shares Acquired by Sheaff Brock Investment Advisors LLC

Sheaff Brock Investment Advisors LLC boosted its position in shares of Pfizer Inc. (NYSE:PFEFree Report) by 1.8% in the third quarter, HoldingsChannel.com reports. The fund owned 80,587 shares of the biopharmaceutical company’s stock after purchasing an additional 1,390 shares during the period. Sheaff Brock Investment Advisors LLC’s holdings in Pfizer were worth $2,673,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. RB Capital Management LLC raised its holdings in shares of Pfizer by 6.7% in the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock worth $282,000 after acquiring an additional 341 shares during the last quarter. Ironwood Wealth Management LLC. increased its position in Pfizer by 1.1% in the 1st quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock valued at $1,868,000 after acquiring an additional 400 shares during the period. United Bank increased its position in Pfizer by 0.6% in the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after acquiring an additional 290 shares during the period. Ergoteles LLC boosted its stake in Pfizer by 136.3% during the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock valued at $1,903,000 after purchasing an additional 21,209 shares in the last quarter. Finally, Mackenzie Financial Corp boosted its stake in shares of Pfizer by 6.4% during the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock worth $69,238,000 after acquiring an additional 79,887 shares in the last quarter. 68.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on PFE shares. UBS Group cut their price objective on Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a report on Thursday, December 14th. Morgan Stanley dropped their price objective on Pfizer from $39.00 to $37.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 1st. BMO Capital Markets decreased their target price on Pfizer from $44.00 to $33.00 and set an “outperform” rating on the stock in a research report on Monday, October 16th. Citigroup decreased their target price on Pfizer from $42.00 to $35.00 and set a “neutral” rating on the stock in a research report on Monday, October 16th. Finally, Truist Financial decreased their price objective on Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, December 14th. Eleven analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $37.13.

Get Our Latest Analysis on Pfizer

Insider Transactions at Pfizer

In other news, Director Scott Gottlieb acquired 3,000 shares of the business’s stock in a transaction on Friday, December 15th. The shares were acquired at an average price of $26.47 per share, for a total transaction of $79,410.00. Following the completion of the transaction, the director now directly owns 9,000 shares of the company’s stock, valued at approximately $238,230. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.05% of the company’s stock.

Pfizer Stock Up 3.9 %

NYSE PFE traded up $1.03 during trading hours on Tuesday, reaching $27.60. 35,553,384 shares of the company’s stock traded hands, compared to its average volume of 46,243,859. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.38 and a quick ratio of 2.05. The firm has a market cap of $155.84 billion, a PE ratio of 76.36, a PEG ratio of 1.20 and a beta of 0.62. Pfizer Inc. has a 52-week low of $25.76 and a 52-week high of $44.33. The firm has a 50-day simple moving average of $28.37 and a 200 day simple moving average of $31.64.

Pfizer (NYSE:PFEGet Free Report) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.61%. The firm had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same period in the previous year, the business posted $1.14 earnings per share. The business’s revenue for the quarter was down 41.3% on a year-over-year basis. Sell-side analysts anticipate that Pfizer Inc. will post 2.23 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 1st. Stockholders of record on Friday, January 26th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.09%. The ex-dividend date of this dividend is Thursday, January 25th. This is an increase from Pfizer’s previous quarterly dividend of $0.41. Pfizer’s payout ratio is 466.67%.

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Recommended Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.